GlassScriptPhysician profile
Carlos M Cazares
NPI 1649237488
$8,322.56
in general payments reported to CMS, 2019-2025
33 companies · $2,113 in 2025
The $2,113 reported for 2025 was more than what 97% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,445 · 2020: $700 · 2021: $1,016 · 2022: $556 · 2023: $608 · 2024: $885 · 2025: $2,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,605.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,358.98 | 2019-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $989.22 | 2019-2025 | Enhertu, Farxiga |
| Lilly USA, LLC | $519.86 | 2019-2024 | Mounjaro, Trulicity |
| Amgen INC. | $507.33 | 2022-2025 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $425.13 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $400.11 | 2019 | |
| Madrigal Pharmaceuticals | $397.64 | 2025 | Rezdiffra |
| Amarin Pharma, INC. | $387.55 | 2019-2020 | |
| Medtronic, INC. | $368.85 | 2023-2025 | Intellis Adaptivestim, Venaseal |
| Teva Pharmaceuticals USA, INC. | $330.13 | 2019-2021 | |
| Eisai INC. | $238.60 | 2024-2025 | |
| Edwards Lifesciences Corporation | $174.65 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $172.11 | 2019 | |
| Impulse Dynamics (USA) INC. | $158.88 | 2025 | Optimizer |
| Glaxosmithkline, LLC. | $151.40 | 2020-2023 | Shingrix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $149.31 | 2019 | |
| Biosense Webster, INC. | $144.65 | 2025 | Carto 3 |
| Stemline Therapeutics INC. | $142.23 | 2025 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.42 | 2021-2023 | Jardiance |
| Davol INC. | $136.49 | 2021 | |
| Inspire Medical Systems, INC. | $117.53 | 2023 | Inspire |
| Acadia Pharmaceuticals INC | $117.05 | 2024 | Daybue |
| Shire North American Group INC | $115.99 | 2019 | |
| Abbott Laboratories | $111.01 | 2025 | Eterna |
| Kyowa Kirin, INC. | $108.60 | 2021 | |
| Phathom Pharmaceuticals, INC. | $107.17 | 2024 | Voquezna |
| Rare Disease Therapeutics, INC. | $96.84 | 2019 | |
| Allergan, INC. | $88.99 | 2019 | |
| Angiodynamics, INC. | $78.25 | 2025 | Auryon Laser System 100-120 Vac |
| Penumbra, INC. | $33.76 | 2025 | Indigo System |
| Pfizer INC. | $26.50 | 2023-2025 | |
| Exact Sciences Corporation | $15.24 | 2025 | The Cologuard Plus Collection Kit |
| Seqirus USA INC | $15.09 | 2025 | Flucelvax, Fluad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Cazares listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.